20559-55-1 | Oxibendazole

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$6.00	$4.00
50mg	98%	in stock	$9.00	$6.00
100mg	98%	in stock	$11.00	$8.00
250mg	98%	in stock	$13.00	$9.00
1g	98%	in stock	$23.00	$17.00
25g	98%	in stock	$217.00	$152.00
100g	98%	in stock	$725.00	$508.00

Description

• Catalog Number: AB06386
• Chemical Name: Oxibendazole
• CAS Number: 20559-55-1
• Molecular Formula: C12H15N3O3
• Molecular Weight: 249.2658
• MDL Number: MFCD00133728
• SMILES: CCCOc1ccc2c(c1)[nH]c(n2)NC(=O)OC
• NSC Number: 758459

Computed Properties

• Complexity: 288
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 18
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5
• XLogP3: 2.4

Literature

• Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.

  Scientific reports 20140101

• FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.

  Chemico-biological interactions 20130905

• Development of an Evidence biochip array kit for the multiplex screening of more than 20 anthelmintic drugs.

  Analytical and bioanalytical chemistry 20120701

• Further evaluation in field tests of the activity of three anthelmintics (fenbendazole, oxibendazole, and pyrantel pamoate) against the ascarid Parascaris equorum in horse foals on eight farms in Central Kentucky (2009-2010).

  Parasitology research 20111001

• Potential drug development candidates for human soil-transmitted helminthiases.

  PLoS neglected tropical diseases 20110601

• Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway.

  Archives of toxicology 20110301

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes.

  BMC veterinary research 20100101

• Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.

  Bioorganic & medicinal chemistry letters 20091201

• Species-specific identification of equine cyathostomes resistant to fenbendazole and susceptible to oxibendazole and moxidectin by macroarray probing.

  Experimental parasitology 20090101

• Equine cyathostomins: a review of biology, clinical significance and therapy.

  Parasites & vectors 20090101

• Anthelmintic resistance in cyathostomin populations from horse yards in Italy, United Kingdom and Germany.

  Parasites & vectors 20090101

• Determination of genomic DNA sequences for beta-tubulin isotype 1 from multiple species of cyathostomin and detection of resistance alleles in third-stage larvae from horses with naturally acquired infections.

  Parasites & vectors 20090101

• Restrictions of anthelmintic usage: perspectives and potential consequences.

  Parasites & vectors 20090101

• Diagnosis and control of anthelmintic-resistant Parascaris equorum.

  Parasites & vectors 20090101

• The little-known scenario of anthelmintic resistance in equine cyathostomes in Italy.

  Annals of the New York Academy of Sciences 20081201

• Evaluation of parasiticidal activity of fenbendazole, ivermectin, oxibendazole, and pyrantel pamoate in horse foals with emphasis on ascarids (Parascaris equorum) in field studies on five farms in Central Kentucky in 2007.

  Parasitology research 20080701

• Field studies indicating reduced activity of ivermectin on small strongyles in horses on a farm in Central Kentucky.

  Parasitology research 20080601

• Study (1991 to 2001) of drug-resistant Population B small strongyles in critical tests in horses in Kentucky at the termination of a 40-year investigation.

  Parasitology research 20070801

• Parasite field study in central Kentucky on thoroughbred foals (born in 2004) treated with pyrantel tartrate daily and other parasiticides periodically.

  Parasitology research 20070201

• Field studies on endoparasites of Thoroughbred foals on seven farms in central Kentucky in 2004.

  Parasitology research 20060401

• Comparative study of sample preparation methods; supported liquid membrane and solid phase extraction in the determination of benzimidazole anthelmintics in biological matrices by liquid chromatography-electrospray-mass spectrometry.

  Talanta 20060315

• Prevalence of anthelmintic resistant cyathostomes on horse farms.

  Journal of the American Veterinary Medical Association 20040915

• Evaluation of a larval development assay (DrenchRite) for the detection of anthelmintic resistance in cyathostomin nematodes of horses.

  Veterinary parasitology 20040507

• Quantitative chromatographic determination of several benzimidazole anthelmintic molecules in parasite material.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20031205

• Population-S benzimidazole- and tetrahydropyrimidine-resistant small strongyles in a pony herd in Kentucky (1977-1999): effects of anthelmintic treatment on the parasites as determined in critical tests.

  Parasitology research 20031101

• Transtegumental diffusion of benzimidazole anthelmintics into Moniezia benedeni: correlation with their octanol-water partition coefficients.

  Experimental parasitology 20030101

• An introductory survey of helminth control practices in south africa and anthelmintic resistance on Thoroughbred stud farms in the Western Cape Province.

  Journal of the South African Veterinary Association 20021201

• Development and validation of a liquid chromatographic-electrospray tandem mass spectrometric multiresidue method for anthelmintics in milk.

  Journal of chromatography. A 20021108

• HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies.

  Journal of pharmaceutical and biomedical analysis 20021015

• One season of pasture exposure fails to induce a protective resistance to cyathostomes but increases numbers of hypobiotic third-stage larvae.

  The Journal of parasitology 20020801

• Evaluation of tests for anthelmintic resistance in cyathostomes.

  Veterinary parasitology 20020702

• Plasma disposition, faecal excretion and in vitro metabolism of oxibendazole following oral administration in horses.

  Research in veterinary science 20020201

• Continuance of studies on Population S benzimidazole-resistant small strongyles in a Shetland pony herd in Kentucky: effect of pyrantel pamoate (1992-1999).

  Veterinary parasitology 20010120

• Ultrastructural changes in Ascaris suum after oxibendazole treatment.

  African journal of health sciences 19980201

• In vitro susceptibilities of the AIDS-associated microsporidian Encephalitozoon intestinalis to albendazole, its sulfoxide metabolite, and 12 additional benzimidazole derivatives.

  Antimicrobial agents and chemotherapy 19971201

• Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice.

  The Journal of parasitology 19951001

• Susceptibility of Encephalitozoon cuniculi to several drugs in vitro.

  Antimicrobial agents and chemotherapy 19950601

• In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles.

  Antimicrobial agents and chemotherapy 19940201